I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
I-Mab (NASDAQ: IMAB), a US-based global clinical-stage biotech company focused on developing immunotherapies for cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The company's management team, including Interim CEO Sean Fu and CMO Phillip Dennis, will present at 5:00 PM ET.
The event will also feature one-on-one and small group meetings from September 9-10, with additional management participants including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler. A webcast of the presentation will be available on I-Mab's IR website under the 'Event Calendar' section.
I-Mab (NASDAQ: IMAB), un'azienda biotecnologica globale in fase clinica con sede negli Stati Uniti e focalizzata sullo sviluppo di immunoterapie per il trattamento del cancro, ha annunciato la sua partecipazione alla 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright il 10 settembre 2024. Il team di gestione dell'azienda, compresi il CEO ad interim Sean Fu e il CMO Phillip Dennis, presenterà alle 17:00 ET.
L'evento includerà anche incontri one-to-one e piccoli gruppi dal 9 al 10 settembre, con ulteriori partecipanti della gestione come il CFO Joe Skelton e il Direttore Senior delle Relazioni con gli Investitori Tyler Ehler. Una diretta web della presentazione sarà disponibile sul sito delle relazioni con gli investitori di I-Mab nella sezione 'Calendario Eventi'.
I-Mab (NASDAQ: IMAB), una empresa biotecnológica global en etapa clínica con sede en EE. UU. que se centra en el desarrollo de inmunoterapias para el tratamiento del cáncer, ha anunciado su participación en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright el 10 de septiembre de 2024. El equipo de gestión de la empresa, incluyendo al CEO interino Sean Fu y al CMO Phillip Dennis, presentará a las 5:00 PM ET.
El evento también contará con reuniones uno a uno y en grupos pequeños del 9 al 10 de septiembre, con participantes adicionales de la gestión, como el CFO Joe Skelton y el Director Senior de Relaciones con Inversores Tyler Ehler. Se podrá acceder a una transmisión en vivo de la presentación en el sitio de IR de I-Mab en la sección 'Calendario de Eventos'.
I-Mab (NASDAQ: IMAB)은 미국에 본사를 둔 글로벌 임상 단계 생명공학 회사로, 암 치료를 위한 면역 요법 개발에 집중하고 있으며, 2024년 9월 10일 H.C. Wainwright 제26회 연간 글로벌 투자 컨퍼런스에 참여할 것이라고 발표했습니다. 회사 경영진, 임시 CEO Sean Fu와 CMO Phillip Dennis가 오후 5시 ET에 발표할 예정입니다.
이 이벤트는 9월 9일부터 10일까지 1:1 및 소그룹 회의도 진행되며, CFO Joe Skelton과 투자자 관계 수석 이사 Tyler Ehler와 같은 추가 경영진도 참석할 예정입니다. 발표의 웹캐스트는 I-Mab의 IR 웹사이트 '이벤트 캘린더' 섹션에서 확인할 수 있습니다.
I-Mab (NASDAQ: IMAB), une entreprise biopharmaceutique mondiale en phase clinique basée aux États-Unis, se concentre sur le développement d'immunothérapies pour le traitement du cancer, a annoncé sa participation à la 26e Conférence Annuelle d'Investissement Mondial H.C. Wainwright le 10 septembre 2024. L'équipe de direction de l'entreprise, dirigée par le PDG par intérim Sean Fu et le CMO Phillip Dennis, présentera à 17 h ET.
L'événement comprendra également des réunions individuelles et en petits groupes du 9 au 10 septembre, avec des participants supplémentaires de la direction, y compris le CFO Joe Skelton et le Directeur Senior des Relations avec les Investisseurs Tyler Ehler. Un webcast de la présentation sera disponible sur le site IR d'I-Mab dans la section 'Calendrier des Événements'.
I-Mab (NASDAQ: IMAB), ein in den USA ansässiges globales biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Immuntherapien zur Krebsbehandlung konzentriert, hat seine Teilnahme an der 26. jährlichen internationalen Investorenkonferenz von H.C. Wainwright am 10. September 2024 bekannt gegeben. Das Managementteam des Unternehmens, einschließlich Interim-CEO Sean Fu und CMO Phillip Dennis, wird um 17:00 Uhr ET präsentieren.
Die Veranstaltung wird auch Einzel- und Gruppengespräche vom 9. bis 10. September umfassen, und weitere Mitglieder der Geschäftsführung, wie CFO Joe Skelton und Senior Director of Investor Relations Tyler Ehler, werden teilnehmen. Ein Webcast der Präsentation wird auf der IR-Website von I-Mab im Bereich 'Veranstaltungskalender' verfügbar sein.
- None.
- None.
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Time | Tuesday, September 10 at 5:00 PM ET |
Presenters | Sean Fu, PhD, Interim Chief Executive Officer (CEO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) |
Webcast link | |
Meetings | One-on-one and small group meetings: September 9 – 10, 2024 |
Management | Sean Fu, PhD, Interim CEO Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, CMO Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under "Event Calendar" on I-Mab's IR website
at https://ir.i-mabbiopharma.com/
For more information, please contact your H.C. Wainwright representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-hc-wainwright-26th-annual-global-investment-conference-302230144.html
SOURCE I-Mab Biopharma
FAQ
When is I-Mab (IMAB) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for I-Mab (IMAB) at the conference?
What type of meetings will I-Mab (IMAB) be conducting at the conference?
Where can investors access the webcast of I-Mab's (IMAB) presentation?
